KemPharm on Monday announced results from a pivotal trial of its attention-deficit/hyperactivity disorder drug KP415 in children ages six through 12.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,